On April 23, 2026, the U.S. Department of Justice and Drug Enforcement Administration (DEA) revealed the Final Order of the December 18, 2025 Executive Order on Increasing Medical Marijuana and Cannabidiol Research, reclassifying medical marijuana from a Schedule I to a Schedule III controlled substance. Both FDA-approved products containing marijuana and medical marijuana regulated by state law are now considered Schedule III controlled substances, putting them in the same class as anabolic steroids and ketamine. This reclassification enshrines the medical validity of marijuana, moving it from the category of “drugs with no currently accepted medical use and a high potential for abuse” to the category of “drugs with moderate to low potential for physical and psychological dependence”, according to the DEA’s website. A hearing has also been scheduled to potentially reclassify recreational marijuana as a Schedule III controlled substance on June 29, 2026. But what does this mean for the legal cannabis world?
Truthfully, it doesn’t improve access as much as one would think. State licensed medical marijuana dispensaries, manufacturers, and providers must submit their existing state credentials to the DEA for registration. The application fees will be $3,699 annually for manufacturers, $1,850 annually for distributors, and $888 for a three-year dispenser registration. Applications that are submitted within 60 days of publication of the upcoming notice of hearing in the Federal Register can continue operating under their state licenses while under review. The DEA plans to approve these first applications within six months. The DEA is expected to leave individual state infrastructure mostly intact for operational requirements, tracking, and reporting, requiring only a federally standardized prescription consisting of the patient’s name, address, and provider information. DEA registration does not replace the necessity of a state license, and will be automatically suspended should a state license be rescinded.
Registered manufacturers will have to sell marijuana crops directly to the DEA, who will facilitate a purchase-and-resale transaction with an added administrative fee to comply with the agency’s role as the sole purchaser of marijuana production. Crops also must be stored in DEA approved facilities during this process. Interstate transportation will still be heavily restricted, just under Schedule III-V controlled substance import/export permits.
This reclassification will mark a positive change in federal income tax deductions for medical marijuana businesses. Previously, under Section 280E of the Internal Revenue Code, businesses engaged in trafficking Schedule I or II substances were only eligible for deductions on the cost of goods sold. Now that medical marijuana is a Schedule III controlled substance, Section 280E no longer applies. However, it is still unclear how this will affect businesses that handle both medical and recreational, or solely recreational while it remains Schedule I.
While this is a step forward in the ongoing battle for common sense marijuana legislation, it is not a federal green light on interstate transportation or ease of access, nor does it affect recreational marijuana. It mostly translates to an interim bureaucracy change and additional registration fees for businesses already in compliance with state laws. It is good news for the medical community, federally acknowledging the long established medical uses of marijuana, and opens the door to more rigorous medical research. However, from a business perspective, it is a long way from the finish line. It once again leaves businesses and providers navigating grey areas that even the federal government cannot concretely define, and will likely change with the June 29th hearing on recreational marijuana. While this step-down is undeniably progress, it leaves a lot to be desired in practice.
